

Carlisle

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	6.0	nc	(nc-nc)	Male	7	4.0	174.8	(70.0-360.2)
Female	1	1.6	nc	(nc-nc)	Female	6	2.7	225.5	(82.4-490.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	23	22.3	103.0	(65.3-154.5)	Female	5	2.4	208.9	(67.3-487.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	1.1	nc	(nc-nc)
Male	8	6.8	117.5	(50.6-231.5)	<u>Ovary</u>				
Female	2	5.0	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.8	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	27	24.8	109.1	(71.9-158.7)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.4	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	4	1.5	nc	(nc-nc)
<u>Leukemia</u>					Female	7	4.0	173.5	(69.5-357.6)
Male	1	2.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.3	nc	(nc-nc)	Female	6	5.3	112.8	(41.2-245.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.3	nc	(nc-nc)	Male	71	85.1	83.5	(65.2-105.3)
Female	1	0.6	nc	(nc-nc)	Female	68	69.7	97.5	(75.7-123.6)
<u>Lung and Bronchus</u>									
Male	3	11.4	nc	(nc-nc)					
Female	3	9.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Carver

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	13.3	112.9	(63.1-186.2)	Male	8	8.7	92.4	(39.8-182.1)
Female	11	4.8	230.8	(115.1-413.0)	Female	14	6.8	207.3	(113.2-347.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.5	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	3	2.1	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	7	7.6	92.2	(37.0-190.1)
Female	42	52.7	79.7	(57.4-107.7)	Female	14	6.4	217.9	(119.0-365.6)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.8	nc	(nc-nc)	Male	6	6.2	97.5	(35.6-212.1)
<u>Colon / Rectum</u>					Female	1	2.7	nc	(nc-nc)
Male	13	14.6	89.1	(47.4-152.4)	<u>Ovary</u>				
Female	13	14.4	90.3	(48.1-154.5)	Female	6	4.8	125.1	(45.7-272.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.6	138.7	(44.7-323.7)	Male	5	4.5	110.2	(35.5-257.1)
Female	0	0.9	nc	(nc-nc)	Female	4	4.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.0	nc	(nc-nc)	Male	51	48.5	105.1	(78.2-138.2)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.1	nc	(nc-nc)
Male	6	7.3	82.5	(30.1-179.7)	Female	0	1.8	nc	(nc-nc)
Female	6	4.2	143.3	(52.3-311.9)	<u>Testis</u>				
<u>Larynx</u>					Male	5	1.6	312.6	(100.7-729.5)
Male	2	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	3.3	nc	(nc-nc)
<u>Leukemia</u>					Female	7	9.5	73.6	(29.5-151.6)
Male	5	5.2	95.9	(30.9-223.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.8	nc	(nc-nc)	Female	14	12.2	114.3	(62.4-191.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	4.6	nc	(nc-nc)	Male	183	178.3	102.6	(88.3-118.6)
Female	2	1.5	nc	(nc-nc)	Female	197	177.5	111.0	(96.0-127.6)
<u>Lung and Bronchus</u>									
Male	33	24.4	135.2	(93.0-189.9)					
Female	34	25.2	135.1	(93.5-188.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Charlemont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	1.8	nc	(nc-nc)	Male	3	1.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	11	6.1	181.3	(90.4-324.5)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.3	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Ovary</u>				
Female	2	1.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	6.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	2	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.1	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	24	24.2	99.1	(63.5-147.4)
Female	0	0.2	nc	(nc-nc)	Female	21	20.1	104.5	(64.7-159.8)
<u>Lung and Bronchus</u>									
Male	2	3.4	nc	(nc-nc)					
Female	1	2.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Charlton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	12.8	109.3	(59.7-183.4)	Male	4	8.6	nc	(nc-nc)
Female	5	4.5	112.1	(36.1-261.7)	Female	4	6.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	2.6	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	Female	5	1.9	260.9	(84.1-608.9)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	9	7.7	117.2	(53.5-222.4)
Female	56	52.3	107.0	(80.8-139.0)	Female	3	6.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	1.9	nc	(nc-nc)	Male	3	6.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.6	nc	(nc-nc)
Male	11	14.8	74.2	(37.0-132.8)	<u>Ovary</u>				
Female	13	14.3	91.1	(48.4-155.7)	Female	3	4.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.5	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	5	4.4	114.3	(36.8-266.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.1	nc	(nc-nc)	Male	25	45.9	54.4	(35.2-80.3)
Female	1	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.1	nc	(nc-nc)
Male	7	7.3	96.2	(38.5-198.2)	Female	0	1.8	nc	(nc-nc)
Female	3	4.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.8	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	3	0.6	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Leukemia</u>					Female	10	10.4	96.0	(46.0-176.6)
Male	3	5.3	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.7	nc	(nc-nc)	Female	13	11.4	113.7	(60.5-194.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.5	nc	(nc-nc)	Male	136	174.5	77.9	(65.4-92.2)
Female	1	1.4	nc	(nc-nc)	Female	186	173.0	107.5	(92.6-124.1)
<u>Lung and Bronchus</u>									
Male	22	22.9	96.1	(60.2-145.6)					
Female	31	22.6	137.1	(93.1-194.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chatham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	16.1	93.3	(52.2-153.9)	Male	23	8.7	264.1	(167.4-396.4)
Female	11	5.5	201.5	(100.4-360.5)	Female	11	5.7	193.3	(96.4-345.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	2.0	251.5	(81.0-586.8)	Male	2	2.7	nc	(nc-nc)
Female	2	1.7	nc	(nc-nc)	Female	4	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	5	7.7	65.2	(21.0-152.1)
Female	58	45.2	128.3	(97.4-165.9)	Female	7	6.5	107.6	(43.1-221.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	1.2	nc	(nc-nc)	Male	8	5.3	151.3	(65.2-298.2)
<u>Colon / Rectum</u>					Female	1	2.6	nc	(nc-nc)
Male	17	15.6	109.2	(63.6-174.9)	<u>Ovary</u>				
Female	14	15.6	89.6	(49.0-150.4)	Female	4	4.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.7	nc	(nc-nc)	Male	7	5.1	137.5	(55.1-283.3)
Female	0	1.0	nc	(nc-nc)	Female	5	5.4	92.9	(29.9-216.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	47	47.4	99.2	(72.9-132.0)
Female	1	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	3.4	nc	(nc-nc)
Male	6	6.6	91.2	(33.3-198.5)	Female	0	2.0	nc	(nc-nc)
Female	5	4.0	125.3	(40.4-292.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	4	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	5.6	nc	(nc-nc)
Male	6	5.4	111.3	(40.6-242.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.7	nc	(nc-nc)	Female	9	10.7	84.3	(38.4-160.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	4.2	nc	(nc-nc)	Male	184	182.7	100.7	(86.7-116.4)
Female	2	1.5	nc	(nc-nc)	Female	193	167.7	115.1	(99.4-132.6)
<u>Lung and Bronchus</u>									
Male	20	27.8	72.0	(43.9-111.1)					
Female	28	27.3	102.7	(68.2-148.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelmsford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	39	39.9	97.7	(69.5-133.5)	Male	25	25.6	97.5	(63.1-144.0)
Female	16	14.9	107.7	(61.5-175.0)	Female	25	20.5	122.2	(79.1-180.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.3	109.8	(47.3-216.4)	Male	10	7.6	131.9	(63.1-242.6)
Female	5	6.3	79.5	(25.6-185.5)	Female	7	6.3	110.9	(44.4-228.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.3	nc	(nc-nc)	Male	24	22.6	106.4	(68.1-158.3)
Female	180	159.5	112.8	(97.0-130.6)	Female	17	19.7	86.3	(50.3-138.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.4	92.6	(29.8-216.1)	Male	21	18.0	116.7	(72.2-178.4)
<u>Colon / Rectum</u>					Female	8	8.2	98.0	(42.2-193.2)
Male	39	43.7	89.2	(63.4-121.9)	<u>Ovary</u>				
Female	47	45.0	104.5	(76.8-138.9)	Female	16	14.5	110.3	(63.0-179.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	10.6	84.7	(38.6-160.7)	Male	12	13.5	88.6	(45.7-154.8)
Female	5	2.9	175.1	(56.4-408.7)	Female	19	14.5	131.1	(78.9-204.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.9	nc	(nc-nc)	Male	110	141.3	77.9	(64.0-93.9)
Female	5	2.4	210.2	(67.7-490.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	9.3	nc	(nc-nc)
Male	22	21.4	103.0	(64.5-155.9)	Female	6	5.6	106.3	(38.8-231.4)
Female	8	12.7	62.8	(27.0-123.7)	<u>Testis</u>				
<u>Larynx</u>					Male	7	4.6	151.7	(60.8-312.6)
Male	6	5.9	102.3	(37.3-222.6)	<u>Thyroid</u>				
Female	3	2.0	nc	(nc-nc)	Male	14	9.6	146.0	(79.8-245.0)
<u>Leukemia</u>					Female	36	28.4	127.0	(88.9-175.8)
Male	19	15.6	121.8	(73.3-190.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	25	11.6	215.1	(139.2-317.6)	Female	42	36.2	115.9	(83.5-156.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	13.4	82.4	(41.1-147.4)	Male	495	526.7	94.0	(85.9-102.6)
Female	3	4.4	nc	(nc-nc)	Female	596	541.5	110.1	(101.4-119.3)
<u>Lung and Bronchus</u>									
Male	71	72.4	98.0	(76.6-123.7)					
Female	76	77.4	98.2	(77.4-123.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chelsea

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	24.2	90.9	(57.0-137.7)	Male	7	17.4	40.1	(16.1-82.7)
Female	9	8.8	102.2	(46.6-194.0)	Female	7	14.9	47.0	(18.8-96.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.9	117.7	(47.1-242.4)	Male	4	4.8	nc	(nc-nc)
Female	3	4.8	nc	(nc-nc)	Female	3	3.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	17	15.6	109.3	(63.6-174.9)
Female	85	101.7	83.6	(66.8-103.4)	Female	17	12.4	136.7	(79.6-219.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	4.3	208.0	(94.9-394.8)	Male	6	12.2	49.3	(18.0-107.3)
<u>Colon / Rectum</u>					Female	7	5.1	136.3	(54.6-280.8)
Male	31	28.3	109.7	(74.5-155.8)	<u>Ovary</u>				
Female	25	27.8	89.8	(58.1-132.5)	Female	3	9.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	6.6	91.3	(33.3-198.7)	Male	9	8.4	107.6	(49.1-204.3)
Female	1	1.7	nc	(nc-nc)	Female	16	8.6	185.5	(105.9-301.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	3.2	nc	(nc-nc)	Male	63	86.7	72.7	(55.8-93.0)
Female	1	2.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	10	5.9	170.5	(81.6-313.6)
Male	12	14.6	82.2	(42.4-143.6)	Female	3	3.5	nc	(nc-nc)
Female	14	8.0	174.1	(95.1-292.1)	<u>Testis</u>				
<u>Larynx</u>					Male	2	6.5	nc	(nc-nc)
Male	5	3.7	136.7	(44.1-319.1)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	7	8.0	87.2	(34.9-179.7)
<u>Leukemia</u>					Female	40	24.2	165.6	(118.3-225.5)
Male	15	11.2	134.3	(75.1-221.5)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	8.2	97.8	(42.1-192.7)	Female	14	22.1	63.2	(34.5-106.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	17	8.6	198.0	(115.3-317.1)	Male	344	342.7	100.4	(90.1-111.6)
Female	5	2.7	185.7	(59.9-433.4)	Female	356	348.2	102.2	(91.9-113.4)
<u>Lung and Bronchus</u>									
Male	71	43.6	163.0	(127.3-205.6)					
Female	55	44.8	122.6	(92.4-159.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cheshire

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	4.4	114.1	(36.8-266.3)	Male	8	2.8	281.1	(121.0-553.9)
Female	3	1.4	nc	(nc-nc)	Female	1	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.8	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
Female	11	15.4	71.4	(35.6-127.7)	Female	0	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	6	4.8	124.0	(45.3-269.9)	<u>Ovary</u>				
Female	2	4.2	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.3	nc	(nc-nc)	Male	22	17.1	129.0	(80.8-195.3)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.0	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.7	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	5	3.6	138.4	(44.6-323.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.5	nc	(nc-nc)	Male	76	59.9	126.9	(100.0-158.8)
Female	0	0.4	nc	(nc-nc)	Female	38	51.3	74.0	(52.4-101.6)
<u>Lung and Bronchus</u>									
Male	15	8.1	184.1	(103.0-303.7)					
Female	3	7.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chester

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.7	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	4	5.9	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.3	nc	(nc-nc)
Male	3	1.9	nc	(nc-nc)	<u>Ovary</u>				
Female	0	1.5	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.5	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	9	6.4	141.2	(64.4-268.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	0.6	nc	(nc-nc)	Male	27	23.0	117.6	(77.5-171.1)
Female	0	0.2	nc	(nc-nc)	Female	13	19.2	67.9	(36.1-116.1)
<u>Lung and Bronchus</u>									
Male	4	3.1	nc	(nc-nc)					
Female	4	2.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chesterfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.5	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.3	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	2	5.7	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	0	1.7	nc	(nc-nc)	<u>Ovary</u>				
Female	1	1.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	4	6.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.4	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.6	nc	(nc-nc)	Male	14	21.1	66.4	(36.3-111.4)
Female	0	0.1	nc	(nc-nc)	Female	9	18.3	49.1	(22.4-93.3)
<u>Lung and Bronchus</u>									
Male	3	2.8	nc	(nc-nc)					
Female	1	2.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chicopee

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	67	62.8	106.7	(82.7-135.5)	Male	25	39.8	62.8	(40.6-92.7)
Female	17	24.8	68.4	(39.8-109.5)	Female	20	33.3	60.1	(36.7-92.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	11.3	88.2	(42.2-162.3)	Male	11	11.7	93.9	(46.8-168.1)
Female	11	10.3	106.7	(53.2-191.0)	Female	8	10.4	76.8	(33.1-151.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.9	nc	(nc-nc)	Male	31	35.2	88.0	(59.8-125.0)
Female	236	248.7	94.9	(83.2-107.8)	Female	34	32.2	105.5	(73.0-147.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	8	8.4	95.3	(41.0-187.8)	Male	29	27.5	105.5	(70.7-151.5)
<u>Colon / Rectum</u>					Female	25	13.2	189.3	(122.5-279.5)
Male	88	68.1	129.2	(103.6-159.2)	<u>Ovary</u>				
Female	82	74.9	109.5	(87.1-136.0)	Female	30	23.2	129.4	(87.3-184.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	16	16.4	97.7	(55.8-158.6)	Male	20	21.1	94.7	(57.8-146.3)
Female	4	4.7	nc	(nc-nc)	Female	29	24.3	119.2	(79.8-171.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	4.8	103.8	(33.5-242.3)	Male	165	216.8	76.1	(64.9-88.6)
Female	2	4.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	15	14.5	103.7	(58.0-171.0)
Male	33	32.6	101.2	(69.6-142.1)	Female	17	9.5	179.1	(104.3-286.8)
Female	23	20.4	112.6	(71.4-169.0)	<u>Testis</u>				
<u>Larynx</u>					Male	12	8.0	149.6	(77.2-261.4)
Male	8	9.0	88.7	(38.2-174.7)	<u>Thyroid</u>				
Female	3	3.1	nc	(nc-nc)	Male	8	14.7	54.2	(23.4-106.9)
<u>Leukemia</u>					Female	26	44.8	58.1	(37.9-85.1)
Male	25	24.6	101.7	(65.8-150.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	19.4	82.6	(47.2-134.1)	Female	55	57.0	96.6	(72.7-125.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	20.5	63.3	(33.7-108.2)	Male	789	817.6	96.5	(89.9-103.5)
Female	4	7.3	nc	(nc-nc)	Female	864	872.3	99.1	(92.6-105.9)
<u>Lung and Bronchus</u>									
Male	147	112.5	130.7	(110.4-153.6)					
Female	141	126.0	111.9	(94.2-132.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Chilmark

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.7	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.2	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	5	4.8	103.7	(33.4-242.1)	Female	0	0.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	6	1.8	337.4	(123.2-734.4)	<u>Ovary</u>				
Female	3	1.4	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	10	5.7	175.5	(84.0-322.8)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	2	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	26	21.2	122.7	(80.1-179.8)
Female	0	0.1	nc	(nc-nc)	Female	14	16.5	85.1	(46.5-142.8)
<u>Lung and Bronchus</u>									
Male	1	3.1	nc	(nc-nc)					
Female	2	2.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Clarksburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	2	0.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	3	8.0	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	4	2.6	nc	(nc-nc)	<u>Ovary</u>				
Female	6	2.2	277.7	(101.4-604.4)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	8.6	92.5	(39.8-182.3)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	3	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	28	31.8	87.9	(58.4-127.1)
Female	0	0.2	nc	(nc-nc)	Female	25	26.7	93.5	(60.5-138.0)
<u>Lung and Bronchus</u>									
Male	5	4.5	110.7	(35.7-258.3)					
Female	5	3.9	128.3	(41.4-299.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Clinton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	13.2	120.9	(69.1-196.3)	Male	6	8.9	67.5	(24.6-146.9)
Female	1	5.0	nc	(nc-nc)	Female	6	7.5	79.8	(29.1-173.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	2.7	nc	(nc-nc)	Male	1	2.6	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	Female	1	2.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	7.9	nc	(nc-nc)
Female	63	56.3	112.0	(86.0-143.3)	Female	9	6.8	131.4	(60.0-249.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.1	nc	(nc-nc)	Male	6	6.4	94.2	(34.4-205.0)
<u>Colon / Rectum</u>					Female	2	2.9	nc	(nc-nc)
Male	14	15.0	93.3	(51.0-156.5)	<u>Ovary</u>				
Female	18	15.7	114.9	(68.1-181.6)	Female	1	5.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	3.6	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
Female	4	1.0	nc	(nc-nc)	Female	7	4.9	141.8	(56.8-292.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	52	47.9	108.5	(81.0-142.3)
Female	0	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	3.1	159.0	(51.2-371.1)
Male	2	7.5	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
Female	7	4.4	157.9	(63.2-325.3)	<u>Testis</u>				
<u>Larynx</u>					Male	0	2.1	nc	(nc-nc)
Male	3	2.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	3.6	nc	(nc-nc)
<u>Leukemia</u>					Female	7	11.1	63.3	(25.4-130.4)
Male	5	5.4	91.8	(29.6-214.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	4.1	144.8	(52.9-315.1)	Female	14	12.7	110.5	(60.3-185.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.7	nc	(nc-nc)	Male	168	180.5	93.1	(79.5-108.3)
Female	2	1.5	nc	(nc-nc)	Female	202	190.3	106.2	(92.0-121.9)
<u>Lung and Bronchus</u>									
Male	31	24.0	129.2	(87.8-183.5)					
Female	35	26.0	134.7	(93.8-187.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cohasset

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	9.3	54.0	(17.4-125.9)	Male	9	5.9	153.7	(70.1-291.7)
Female	4	3.4	nc	(nc-nc)	Female	11	4.4	249.4	(124.3-446.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.7	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	5	5.2	96.8	(31.2-225.8)
Female	37	35.3	104.9	(73.9-144.6)	Female	1	4.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.8	nc	(nc-nc)
Male	15	10.1	148.1	(82.8-244.3)	<u>Ovary</u>				
Female	7	10.3	67.9	(27.2-140.0)	Female	3	3.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.4	nc	(nc-nc)	Male	2	3.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.6	nc	(nc-nc)	Male	28	32.2	86.8	(57.7-125.5)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	2.1	nc	(nc-nc)
Male	6	4.9	123.1	(45.0-268.0)	Female	0	1.3	nc	(nc-nc)
Female	5	2.8	177.0	(57.0-413.1)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.9	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
<u>Leukemia</u>					Female	8	5.9	134.5	(57.9-265.0)
Male	1	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.6	nc	(nc-nc)	Female	8	7.9	101.1	(43.5-199.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	3.1	nc	(nc-nc)	Male	103	120.8	85.3	(69.6-103.4)
Female	1	1.0	nc	(nc-nc)	Female	122	120.0	101.6	(84.4-121.4)
<u>Lung and Bronchus</u>									
Male	8	16.7	47.8	(20.6-94.3)					
Female	8	17.1	46.8	(20.2-92.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Colrain

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.2	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	8	7.5	106.8	(46.0-210.4)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.0	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	7	8.5	82.1	(32.9-169.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	0.5	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.2	nc	(nc-nc)
Male	1	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.4	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.5	nc	(nc-nc)	Female	5	1.8	282.5	(91.0-659.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	27	30.4	88.9	(58.6-129.3)
Female	0	0.2	nc	(nc-nc)	Female	30	24.7	121.3	(81.9-173.2)
<u>Lung and Bronchus</u>									
Male	4	4.1	nc	(nc-nc)					
Female	4	3.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Concord

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	26.5	98.1	(64.0-143.7)	Male	33	16.1	204.5	(140.8-287.3)
Female	6	9.6	62.7	(22.9-136.6)	Female	16	11.5	139.6	(79.7-226.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	4.3	116.2	(37.4-271.2)	Male	2	4.8	nc	(nc-nc)
Female	5	3.6	139.3	(44.9-325.0)	Female	3	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.8	nc	(nc-nc)	Male	12	14.3	83.8	(43.2-146.3)
Female	107	91.0	117.6	(96.4-142.1)	Female	12	12.0	100.0	(51.6-174.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	8	10.9	73.5	(31.7-144.8)
<u>Colon / Rectum</u>					Female	1	4.9	nc	(nc-nc)
Male	19	28.3	67.1	(40.4-104.7)	<u>Ovary</u>				
Female	33	28.9	114.4	(78.7-160.6)	Female	11	8.5	130.1	(64.9-232.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	6.6	nc	(nc-nc)	Male	14	8.7	160.1	(87.5-268.7)
Female	0	1.8	nc	(nc-nc)	Female	7	9.4	74.2	(29.7-152.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.6	nc	(nc-nc)	Male	90	85.3	105.5	(84.9-129.7)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	6.0	nc	(nc-nc)
Male	15	12.9	115.9	(64.8-191.3)	Female	0	3.7	nc	(nc-nc)
Female	7	7.5	93.4	(37.4-192.5)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.5	nc	(nc-nc)
Male	0	3.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.2	nc	(nc-nc)	Male	4	5.5	nc	(nc-nc)
<u>Leukemia</u>					Female	12	13.9	86.4	(44.6-151.0)
Male	10	9.9	101.0	(48.3-185.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	7.1	70.3	(22.7-164.1)	Female	24	20.8	115.3	(73.9-171.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	8.2	60.8	(19.6-142.0)	Male	299	330.1	90.6	(80.6-101.4)
Female	4	2.7	nc	(nc-nc)	Female	310	320.2	96.8	(86.3-108.2)
<u>Lung and Bronchus</u>									
Male	19	46.4	40.9	(24.6-63.9)					
Female	24	47.1	51.0	(32.7-75.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Conway

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.3	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	10	9.1	110.0	(52.7-202.4)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	2	2.6	nc	(nc-nc)	<u>Ovary</u>				
Female	2	2.1	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	9.6	83.3	(35.8-164.1)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.2	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.7	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	2	2.2	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	32	32.5	98.3	(67.2-138.8)
Female	0	0.2	nc	(nc-nc)	Female	23	28.7	80.3	(50.9-120.5)
<u>Lung and Bronchus</u>									
Male	3	4.3	nc	(nc-nc)					
Female	1	3.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Cummington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	1.2	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	3	0.7	nc	(nc-nc)
Female	9	4.2	213.0	(97.2-404.3)	Female	1	0.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	3	1.3	nc	(nc-nc)	<u>Ovary</u>				
Female	4	1.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	4.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.8	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.3	nc	(nc-nc)	Female	5	1.0	502.5	(161.9-1172.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	13	16.1	80.5	(42.8-137.7)
Female	0	0.1	nc	(nc-nc)	Female	24	13.8	174.1	(111.5-259.1)
<u>Lung and Bronchus</u>									
Male	1	2.2	nc	(nc-nc)					
Female	1	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dalton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	9.1	120.8	(60.2-216.2)	Male	11	5.6	197.0	(98.2-352.5)
Female	4	3.4	nc	(nc-nc)	Female	3	4.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.5	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	0	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	4	4.9	nc	(nc-nc)
Female	27	33.4	80.8	(53.2-117.5)	Female	4	4.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	1.1	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.8	nc	(nc-nc)
Male	12	9.7	123.5	(63.7-215.7)	<u>Ovary</u>				
Female	11	10.2	108.2	(53.9-193.5)	Female	4	3.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	2.3	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	3.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	32	30.2	106.0	(72.5-149.6)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.1	nc	(nc-nc)
Male	2	4.5	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
Female	1	2.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	5.6	nc	(nc-nc)
Male	1	3.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.6	nc	(nc-nc)	Female	9	7.6	117.8	(53.7-223.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.9	nc	(nc-nc)	Male	102	115.0	88.7	(72.3-107.7)
Female	1	1.0	nc	(nc-nc)	Female	104	116.7	89.1	(72.8-108.0)
<u>Lung and Bronchus</u>									
Male	14	16.1	86.8	(47.4-145.7)					
Female	22	17.0	129.5	(81.1-196.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Danvers

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	39	33.9	114.9	(81.7-157.1)	Male	23	21.0	109.5	(69.4-164.2)
Female	9	13.4	67.2	(30.7-127.6)	Female	17	17.3	98.1	(57.1-157.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	12	5.7	209.0	(107.9-365.2)	Male	3	6.3	nc	(nc-nc)
Female	4	5.3	nc	(nc-nc)	Female	2	5.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.0	nc	(nc-nc)	Male	13	18.6	69.9	(37.2-119.6)
Female	143	132.9	107.6	(90.7-126.7)	Female	27	17.2	157.2	(103.5-228.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.4	nc	(nc-nc)	Male	14	14.3	98.1	(53.6-164.7)
<u>Colon / Rectum</u>					Female	6	7.0	85.3	(31.2-185.7)
Male	29	36.4	79.6	(53.3-114.4)	<u>Ovary</u>				
Female	40	40.8	98.1	(70.1-133.6)	Female	13	12.3	106.0	(56.4-181.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	8.6	127.7	(63.6-228.4)	Male	13	11.3	115.5	(61.4-197.4)
Female	1	2.5	nc	(nc-nc)	Female	12	13.2	91.1	(47.0-159.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.2	nc	(nc-nc)	Male	140	111.7	125.4	(105.5-147.9)
Female	4	2.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	7.7	64.5	(20.8-150.6)
Male	22	17.0	129.4	(81.1-195.9)	Female	7	5.2	135.3	(54.2-278.7)
Female	9	10.8	83.0	(37.9-157.6)	<u>Testis</u>				
<u>Larynx</u>					Male	9	3.5	257.3	(117.4-488.5)
Male	3	4.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.6	nc	(nc-nc)	Male	10	7.4	135.1	(64.7-248.5)
<u>Leukemia</u>					Female	19	22.8	83.4	(50.2-130.3)
Male	18	12.9	139.6	(82.7-220.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	16	10.3	156.0	(89.1-253.3)	Female	34	29.9	113.7	(78.8-159.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	12	10.8	111.6	(57.6-194.9)	Male	477	429.4	111.1	(101.3-121.5)
Female	5	3.9	129.2	(41.6-301.5)	Female	467	464.1	100.6	(91.7-110.2)
<u>Lung and Bronchus</u>									
Male	66	60.2	109.7	(84.8-139.5)					
Female	58	67.0	86.6	(65.7-111.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dartmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	54	39.7	136.2	(102.3-177.7)	Male	21	24.9	84.5	(52.3-129.1)
Female	19	14.6	130.0	(78.2-203.0)	Female	16	19.3	82.8	(47.3-134.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	7.0	113.8	(49.0-224.3)	Male	5	7.3	68.1	(21.9-158.9)
Female	6	6.0	99.9	(36.5-217.5)	Female	6	6.1	98.0	(35.8-213.3)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	21	22.2	94.6	(58.5-144.6)
Female	120	146.3	82.0	(68.0-98.1)	Female	23	18.9	121.4	(76.9-182.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	4.8	125.1	(45.7-272.3)	Male	17	17.1	99.2	(57.8-158.8)
<u>Colon / Rectum</u>					Female	10	7.8	128.7	(61.6-236.6)
Male	39	42.7	91.4	(65.0-125.0)	<u>Ovary</u>				
Female	51	44.2	115.4	(85.9-151.7)	Female	11	13.6	80.6	(40.2-144.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	10.3	106.8	(53.2-191.1)	Male	13	13.3	97.8	(52.0-167.3)
Female	2	2.8	nc	(nc-nc)	Female	7	14.4	48.6	(19.5-100.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.2	nc	(nc-nc)	Male	179	136.2	131.4	(112.8-152.1)
Female	2	2.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	9.1	143.1	(76.1-244.8)
Male	27	20.3	133.3	(87.8-193.9)	Female	8	5.6	142.4	(61.3-280.6)
Female	16	11.9	134.3	(76.7-218.2)	<u>Testis</u>				
<u>Larynx</u>					Male	5	5.2	95.6	(30.8-223.0)
Male	4	5.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.8	nc	(nc-nc)	Male	12	9.2	130.2	(67.2-227.5)
<u>Leukemia</u>					Female	34	25.7	132.1	(91.5-184.7)
Male	19	15.5	122.8	(73.9-191.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	11.3	79.8	(36.4-151.5)	Female	34	33.5	101.6	(70.4-142.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	12.8	62.7	(27.0-123.6)	Male	572	513.6	111.4	(102.4-120.9)
Female	2	4.3	nc	(nc-nc)	Female	467	511.5	91.3	(83.2-100.0)
<u>Lung and Bronchus</u>									
Male	74	70.5	105.0	(82.4-131.8)					
Female	43	73.6	58.4	(42.3-78.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dedham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	37	32.7	113.0	(79.6-155.8)	Male	21	19.9	105.3	(65.2-161.0)
Female	9	12.7	70.7	(32.3-134.2)	Female	23	15.9	144.3	(91.4-216.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	5.4	128.7	(51.6-265.3)	Male	5	5.9	84.5	(27.2-197.2)
Female	4	4.9	nc	(nc-nc)	Female	1	5.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.0	nc	(nc-nc)	Male	20	17.8	112.7	(68.8-174.0)
Female	132	120.9	109.2	(91.3-129.4)	Female	14	16.0	87.4	(47.7-146.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	3.9	152.1	(55.5-331.1)	Male	14	13.3	105.6	(57.7-177.2)
<u>Colon / Rectum</u>					Female	4	6.5	nc	(nc-nc)
Male	32	34.8	91.9	(62.8-129.7)	<u>Ovary</u>				
Female	34	38.6	88.0	(61.0-123.0)	Female	13	11.2	115.8	(61.6-198.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	8.1	74.1	(27.1-161.4)	Male	13	10.7	120.9	(64.3-206.8)
Female	2	2.4	nc	(nc-nc)	Female	16	12.6	127.4	(72.8-207.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.2	nc	(nc-nc)	Male	87	103.3	84.2	(67.5-103.9)
Female	3	1.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	7.4	108.2	(46.6-213.1)
Male	13	15.9	82.0	(43.6-140.3)	Female	6	4.9	121.4	(44.3-264.2)
Female	12	10.0	119.9	(61.9-209.5)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.5	nc	(nc-nc)
Male	3	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.5	nc	(nc-nc)	Male	6	6.9	86.5	(31.6-188.3)
<u>Leukemia</u>					Female	30	20.4	147.0	(99.1-209.8)
Male	9	12.4	72.4	(33.0-137.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	9.7	51.7	(16.7-120.6)	Female	26	27.0	96.4	(63.0-141.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	10.0	100.2	(48.0-184.4)	Male	386	405.6	95.2	(85.9-105.2)
Female	6	3.6	166.7	(60.9-362.8)	Female	444	429.0	103.5	(94.1-113.6)
<u>Lung and Bronchus</u>									
Male	58	56.9	102.0	(77.5-131.9)					
Female	72	62.4	115.4	(90.3-145.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Deerfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	6.3	nc	(nc-nc)	Male	5	4.1	121.6	(39.2-283.7)
Female	4	2.2	nc	(nc-nc)	Female	4	3.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.2	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	22	25.0	88.1	(55.2-133.4)	Female	4	3.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.3	nc	(nc-nc)
Male	6	7.0	86.0	(31.4-187.1)	<u>Ovary</u>				
Female	2	6.7	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.8	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	23	24.3	94.7	(60.0-142.1)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.5	nc	(nc-nc)
Male	7	3.5	199.5	(79.9-411.1)	Female	1	0.8	nc	(nc-nc)
Female	3	2.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	0.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	4	4.4	nc	(nc-nc)
Male	0	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.7	nc	(nc-nc)	Female	2	5.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.2	nc	(nc-nc)	Male	64	86.2	74.2	(57.1-94.8)
Female	0	0.7	nc	(nc-nc)	Female	57	83.2	68.5	(51.9-88.8)
<u>Lung and Bronchus</u>									
Male	3	11.7	nc	(nc-nc)					
Female	4	11.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dennis

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	32	31.1	102.8	(70.3-145.1)	Male	31	17.4	178.0	(120.9-252.7)
Female	11	11.1	98.9	(49.3-176.9)	Female	26	12.3	211.3	(138.0-309.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.1	nc	(nc-nc)	Male	5	5.4	92.5	(29.8-215.9)
Female	2	3.8	nc	(nc-nc)	Female	2	4.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	17	15.3	111.3	(64.8-178.1)
Female	124	98.2	126.3	(105.1-150.6)	Female	13	13.6	95.6	(50.9-163.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	19	10.9	174.0	(104.7-271.7)
<u>Colon / Rectum</u>					Female	4	5.4	nc	(nc-nc)
Male	32	30.7	104.1	(71.2-147.0)	<u>Ovary</u>				
Female	32	31.8	100.6	(68.8-142.0)	Female	10	9.2	108.3	(51.8-199.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.5	106.8	(46.0-210.5)	Male	13	10.0	130.1	(69.2-222.5)
Female	3	2.1	nc	(nc-nc)	Female	10	10.9	92.0	(44.0-169.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	121	96.5	125.3	(104.0-149.8)
Female	2	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	6.7	nc	(nc-nc)
Male	9	13.5	66.6	(30.4-126.4)	Female	4	4.0	nc	(nc-nc)
Female	8	8.5	94.2	(40.6-185.7)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.5	nc	(nc-nc)
Male	2	4.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.4	nc	(nc-nc)	Male	1	4.9	nc	(nc-nc)
<u>Leukemia</u>					Female	17	13.3	128.3	(74.7-205.4)
Male	13	10.7	122.0	(64.9-208.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	7.7	90.4	(36.2-186.3)	Female	26	23.4	111.3	(72.7-163.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	8.6	115.6	(55.3-212.6)	Male	407	365.4	111.4	(100.8-122.7)
Female	3	3.2	nc	(nc-nc)	Female	396	355.7	111.3	(100.6-122.9)
<u>Lung and Bronchus</u>									
Male	51	54.9	93.0	(69.2-122.2)					
Female	55	57.0	96.4	(72.6-125.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dighton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	7.2	97.1	(38.9-200.1)	Male	6	4.8	124.8	(45.6-271.6)
Female	1	2.5	nc	(nc-nc)	Female	5	3.8	133.0	(42.9-310.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.4	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	4.3	nc	(nc-nc)
Female	16	29.2	54.7	(31.2-88.8)	Female	0	3.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.1	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.5	nc	(nc-nc)
Male	13	8.2	158.2	(84.1-270.5)	<u>Ovary</u>				
Female	4	7.8	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.0	nc	(nc-nc)	Male	5	2.5	199.1	(64.2-464.6)
Female	0	0.5	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.6	nc	(nc-nc)	Male	30	27.4	109.5	(73.8-156.3)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.7	nc	(nc-nc)
Male	6	4.1	144.7	(52.8-314.9)	Female	0	1.0	nc	(nc-nc)
Female	4	2.3	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.0	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	4	1.9	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.6	88.7	(28.6-207.1)
Male	0	3.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.1	nc	(nc-nc)	Female	6	6.6	91.4	(33.4-198.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.5	nc	(nc-nc)	Male	98	99.6	98.3	(79.8-119.9)
Female	2	0.8	nc	(nc-nc)	Female	74	96.7	76.6	(60.1-96.1)
<u>Lung and Bronchus</u>									
Male	9	13.1	68.6	(31.3-130.1)					
Female	12	13.1	91.4	(47.2-159.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Douglas

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	9	6.2	144.4	(65.9-274.0)	Male	6	4.8	125.6	(45.9-273.4)
Female	3	2.1	nc	(nc-nc)	Female	6	3.9	155.3	(56.7-338.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.6	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	3	4.2	nc	(nc-nc)
Female	29	29.7	97.7	(65.4-140.3)	Female	2	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.4	nc	(nc-nc)
Male	6	7.9	76.1	(27.8-165.6)	<u>Ovary</u>				
Female	5	6.8	73.2	(23.6-170.9)	Female	2	2.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	1.9	258.4	(83.3-603.1)	Male	4	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	2.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.7	nc	(nc-nc)	Male	24	27.3	87.9	(56.3-130.8)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.6	nc	(nc-nc)
Male	6	4.4	137.9	(50.3-300.1)	Female	0	0.8	nc	(nc-nc)
Female	2	2.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.3	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	6.7	75.1	(24.2-175.3)
Male	1	2.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	1.9	nc	(nc-nc)	Female	9	6.5	138.3	(63.1-262.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	2.6	nc	(nc-nc)	Male	102	97.1	105.1	(85.7-127.5)
Female	0	0.7	nc	(nc-nc)	Female	91	93.0	97.8	(78.8-120.1)
<u>Lung and Bronchus</u>									
Male	11	12.0	91.9	(45.8-164.5)					
Female	13	11.3	114.9	(61.1-196.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	6.6	nc	(nc-nc)	Male	10	4.3	230.2	(110.2-423.3)
Female	0	1.9	nc	(nc-nc)	Female	3	3.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	3.8	209.3	(90.1-412.5)
Female	28	24.4	114.6	(76.1-165.7)	Female	2	2.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.8	nc	(nc-nc)	Male	3	3.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.2	nc	(nc-nc)
Male	5	7.4	67.4	(21.7-157.4)	<u>Ovary</u>				
Female	4	6.0	nc	(nc-nc)	Female	0	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.9	nc	(nc-nc)	Male	1	2.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	2	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	24	26.0	92.5	(59.2-137.6)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	1.6	nc	(nc-nc)
Male	3	3.8	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
Female	1	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
<u>Leukemia</u>					Female	5	4.4	113.6	(36.6-265.1)
Male	2	2.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.6	nc	(nc-nc)	Female	3	5.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	2.4	nc	(nc-nc)	Male	84	91.6	91.7	(73.1-113.5)
Female	0	0.6	nc	(nc-nc)	Female	66	78.2	84.4	(65.3-107.4)
<u>Lung and Bronchus</u>									
Male	5	12.4	40.2	(13.0-93.8)					
Female	6	10.7	55.8	(20.4-121.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dracut

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	39	29.0	134.4	(95.5-183.7)	Male	11	19.5	56.4	(28.1-101.0)
Female	18	10.5	171.3	(101.5-270.8)	Female	17	16.0	106.3	(61.9-170.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	5.8	137.0	(59.0-270.0)	Male	6	5.6	106.2	(38.8-231.2)
Female	6	4.9	121.9	(44.5-265.3)	Female	4	4.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.9	nc	(nc-nc)	Male	18	17.2	104.4	(61.9-165.0)
Female	133	121.8	109.2	(91.4-129.4)	Female	8	14.5	55.3	(23.8-109.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	6	4.4	134.9	(49.3-293.6)	Male	9	14.1	64.0	(29.2-121.5)
<u>Colon / Rectum</u>					Female	8	6.1	131.3	(56.5-258.7)
Male	40	32.8	121.9	(87.1-166.0)	<u>Ovary</u>				
Female	44	32.4	135.7	(98.6-182.2)	Female	14	11.0	127.3	(69.5-213.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	12	8.0	150.4	(77.6-262.7)	Male	5	10.0	50.0	(16.1-116.6)
Female	1	2.0	nc	(nc-nc)	Female	13	10.2	127.9	(68.0-218.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.6	nc	(nc-nc)	Male	98	107.3	91.3	(74.2-111.3)
Female	3	2.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	6.9	nc	(nc-nc)
Male	20	16.5	120.9	(73.8-186.8)	Female	5	4.0	124.0	(40.0-289.3)
Female	8	9.5	84.1	(36.2-165.7)	<u>Testis</u>				
<u>Larynx</u>					Male	1	4.4	nc	(nc-nc)
Male	4	4.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.5	nc	(nc-nc)	Male	6	7.9	75.9	(27.7-165.3)
<u>Leukemia</u>					Female	28	24.0	116.6	(77.5-168.6)
Male	22	11.9	184.9	(115.8-279.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	10	8.7	115.3	(55.2-212.0)	Female	18	27.5	65.4	(38.8-103.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	10.2	nc	(nc-nc)	Male	401	398.2	100.7	(91.1-111.0)
Female	4	3.3	nc	(nc-nc)	Female	459	405.8	113.1	(103.0-123.9)
<u>Lung and Bronchus</u>									
Male	57	53.0	107.5	(81.4-139.3)					
Female	73	55.6	131.4	(103.0-165.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dudley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	11.0	72.8	(31.3-143.4)	Male	4	7.3	nc	(nc-nc)
Female	4	3.7	nc	(nc-nc)	Female	4	5.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.2	nc	(nc-nc)	Male	2	2.1	nc	(nc-nc)
Female	2	1.8	nc	(nc-nc)	Female	0	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	3	6.5	nc	(nc-nc)
Female	36	43.5	82.7	(57.9-114.5)	Female	4	5.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	1.6	nc	(nc-nc)	Male	3	5.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.2	nc	(nc-nc)
Male	14	12.4	113.2	(61.8-189.9)	<u>Ovary</u>				
Female	12	11.6	103.1	(53.2-180.2)	Female	8	3.9	202.7	(87.3-399.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.0	nc	(nc-nc)	Male	5	3.8	132.8	(42.8-309.9)
Female	2	0.7	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.0	nc	(nc-nc)	Male	32	40.0	80.0	(54.7-112.9)
Female	1	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	2.6	nc	(nc-nc)
Male	6	6.2	97.3	(35.5-211.7)	Female	0	1.5	nc	(nc-nc)
Female	3	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.7	nc	(nc-nc)
Male	3	1.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	12	8.7	138.0	(71.2-241.0)
Male	9	4.5	198.6	(90.6-377.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	3.1	nc	(nc-nc)	Female	16	9.8	162.8	(93.0-264.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.8	nc	(nc-nc)	Male	146	149.8	97.4	(82.3-114.6)
Female	0	1.2	nc	(nc-nc)	Female	147	145.1	101.3	(85.6-119.1)
<u>Lung and Bronchus</u>									
Male	28	19.9	140.7	(93.5-203.4)					
Female	23	19.5	117.9	(74.7-176.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Dunstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.8	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	2	0.6	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
Female	16	12.9	124.0	(70.8-201.3)	Female	1	1.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.5	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.6	nc	(nc-nc)
Male	7	3.4	205.5	(82.3-423.5)	<u>Ovary</u>				
Female	1	2.9	nc	(nc-nc)	Female	0	1.1	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	0.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	2	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	8	12.2	65.6	(28.2-129.2)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	4	1.9	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	0.4	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.6	nc	(nc-nc)
Male	2	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.8	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.1	nc	(nc-nc)	Male	42	42.3	99.2	(71.5-134.1)
Female	0	0.3	nc	(nc-nc)	Female	41	39.7	103.3	(74.1-140.1)
<u>Lung and Bronchus</u>									
Male	3	5.4	nc	(nc-nc)					
Female	6	5.0	119.9	(43.8-260.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Duxbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	18.5	129.6	(83.0-192.8)	Male	26	11.7	221.6	(144.7-324.7)
Female	2	6.7	nc	(nc-nc)	Female	14	9.0	155.2	(84.8-260.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.3	150.1	(48.4-350.2)	Male	5	3.5	141.8	(45.7-330.9)
Female	1	2.9	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	11	10.4	105.8	(52.7-189.3)
Female	78	72.4	107.8	(85.2-134.5)	Female	3	8.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.4	nc	(nc-nc)	Male	5	8.5	58.6	(18.9-136.7)
<u>Colon / Rectum</u>					Female	4	3.7	nc	(nc-nc)
Male	11	20.3	54.1	(27.0-96.8)	<u>Ovary</u>				
Female	12	20.4	58.8	(30.3-102.7)	Female	9	6.6	137.0	(62.5-260.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	5.0	158.6	(68.3-312.6)	Male	4	6.4	nc	(nc-nc)
Female	0	1.3	nc	(nc-nc)	Female	5	6.6	76.1	(24.5-177.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.2	nc	(nc-nc)	Male	78	68.8	113.4	(89.7-141.6)
Female	2	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	4.3	nc	(nc-nc)
Male	12	10.0	120.3	(62.1-210.1)	Female	2	2.6	nc	(nc-nc)
Female	3	5.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.7	nc	(nc-nc)
Male	0	2.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	0	4.3	nc	(nc-nc)
<u>Leukemia</u>					Female	15	12.2	122.6	(68.6-202.3)
Male	6	7.2	83.5	(30.5-181.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.3	95.1	(30.6-221.9)	Female	9	16.6	54.1	(24.7-102.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	6.3	nc	(nc-nc)	Male	247	247.1	100.0	(87.9-113.2)
Female	0	2.0	nc	(nc-nc)	Female	207	243.5	85.0	(73.8-97.4)
<u>Lung and Bronchus</u>									
Male	23	33.6	68.4	(43.3-102.6)					
Female	18	34.1	52.9	(31.3-83.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	13.5	111.0	(62.1-183.1)	Male	11	9.2	119.5	(59.6-213.9)
Female	8	4.9	163.6	(70.4-322.3)	Female	11	7.4	147.9	(73.7-264.6)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	1	2.3	nc	(nc-nc)	Female	0	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	8.1	99.1	(42.7-195.2)
Female	47	57.7	81.5	(59.9-108.3)	Female	11	6.8	161.5	(80.5-289.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.1	nc	(nc-nc)	Male	7	6.8	103.2	(41.3-212.6)
<u>Colon / Rectum</u>					Female	2	2.9	nc	(nc-nc)
Male	14	15.4	90.9	(49.6-152.4)	<u>Ovary</u>				
Female	13	15.0	86.7	(46.1-148.2)	Female	5	5.2	96.3	(31.0-224.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.8	130.6	(42.1-304.7)	Male	2	4.7	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	7	4.7	147.8	(59.2-304.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.2	nc	(nc-nc)	Male	47	52.7	89.2	(65.6-118.7)
Female	1	1.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	3	3.2	nc	(nc-nc)
Male	11	8.0	138.0	(68.8-247.0)	Female	0	1.9	nc	(nc-nc)
Female	3	4.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	2	2.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	6	3.8	159.5	(58.3-347.3)
<u>Leukemia</u>					Female	13	11.1	116.8	(62.1-199.7)
Male	2	5.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.0	nc	(nc-nc)	Female	15	13.2	113.5	(63.5-187.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.9	nc	(nc-nc)	Male	189	189.9	99.5	(85.9-114.8)
Female	0	1.5	nc	(nc-nc)	Female	196	190.8	102.7	(88.8-118.2)
<u>Lung and Bronchus</u>									
Male	32	25.2	127.0	(86.8-179.2)					
Female	30	26.2	114.4	(77.2-163.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	2.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	2	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	8	9.0	89.4	(38.5-176.1)	Female	0	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	5	2.8	178.3	(57.5-416.1)	<u>Ovary</u>				
Female	1	2.4	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	8	9.7	82.7	(35.6-163.0)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	1	1.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.7	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	30	34.4	87.1	(58.8-124.3)
Female	0	0.2	nc	(nc-nc)	Female	30	29.8	100.8	(68.0-144.0)
<u>Lung and Bronchus</u>									
Male	1	4.6	nc	(nc-nc)					
Female	4	4.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

East Longmeadow

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	22.0	99.8	(62.5-151.1)	Male	18	13.1	137.1	(81.2-216.6)
Female	4	8.9	nc	(nc-nc)	Female	7	10.6	66.1	(26.5-136.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.5	nc	(nc-nc)	Male	0	3.9	nc	(nc-nc)
Female	0	3.3	nc	(nc-nc)	Female	3	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	11	11.8	93.6	(46.7-167.5)
Female	73	81.0	90.1	(70.6-113.3)	Female	9	11.0	81.9	(37.4-155.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	2.6	nc	(nc-nc)	Male	7	8.7	80.3	(32.2-165.5)
<u>Colon / Rectum</u>					Female	5	4.4	113.2	(36.5-264.1)
Male	15	23.3	64.2	(35.9-106.0)	<u>Ovary</u>				
Female	20	27.1	73.9	(45.1-114.1)	Female	8	7.6	105.7	(45.5-208.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	5.4	nc	(nc-nc)	Male	5	7.2	69.5	(22.4-162.3)
Female	2	1.7	nc	(nc-nc)	Female	13	8.8	147.1	(78.3-251.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.3	nc	(nc-nc)	Male	66	68.2	96.7	(74.8-123.1)
Female	2	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	5.0	121.1	(44.2-263.7)
Male	13	10.4	125.2	(66.6-214.1)	Female	3	3.5	nc	(nc-nc)
Female	11	6.7	163.0	(81.3-291.7)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.9	nc	(nc-nc)
Male	4	2.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	3	4.4	nc	(nc-nc)
<u>Leukemia</u>					Female	9	13.0	69.4	(31.7-131.8)
Male	7	8.2	85.0	(34.0-175.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	6.7	nc	(nc-nc)	Female	12	17.9	67.1	(34.6-117.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.6	nc	(nc-nc)	Male	241	268.8	89.7	(78.7-101.7)
Female	0	2.5	nc	(nc-nc)	Female	254	290.9	87.3	(76.9-98.7)
<u>Lung and Bronchus</u>									
Male	34	38.0	89.5	(62.0-125.1)					
Female	44	42.4	103.7	(75.4-139.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Eastham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	5	11.9	42.2	(13.6-98.4)	Male	8	6.6	121.8	(52.4-239.9)
Female	4	3.8	nc	(nc-nc)	Female	16	4.3	375.5	(214.5-609.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.5	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	3	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	2	5.8	nc	(nc-nc)
Female	46	34.5	133.2	(97.5-177.7)	Female	8	4.7	171.5	(73.8-337.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.9	nc	(nc-nc)	Male	3	4.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	1.9	nc	(nc-nc)
Male	7	11.6	60.1	(24.1-123.9)	<u>Ovary</u>				
Female	11	10.7	102.6	(51.1-183.5)	Female	5	3.2	155.4	(50.1-362.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	2.8	nc	(nc-nc)	Male	2	3.8	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	6	3.7	164.2	(60.0-357.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	41	36.6	112.0	(80.3-151.9)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	2.6	nc	(nc-nc)
Male	4	5.1	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
Female	1	2.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.5	nc	(nc-nc)
Male	0	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.5	nc	(nc-nc)	Male	1	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	2	4.7	nc	(nc-nc)
Male	9	4.0	223.9	(102.2-425.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	2.6	nc	(nc-nc)	Female	7	8.3	84.0	(33.7-173.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.3	nc	(nc-nc)	Male	124	138.3	89.6	(74.6-106.9)
Female	0	1.1	nc	(nc-nc)	Female	145	123.1	117.8	(99.4-138.6)
<u>Lung and Bronchus</u>									
Male	22	20.8	105.9	(66.4-160.4)					
Female	17	19.6	86.5	(50.4-138.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Easthampton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	12	18.3	65.5	(33.8-114.4)	Male	6	12.0	50.2	(18.3-109.3)
Female	3	6.9	nc	(nc-nc)	Female	7	9.9	70.8	(28.3-145.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.4	nc	(nc-nc)	Male	2	3.5	nc	(nc-nc)
Female	2	3.0	nc	(nc-nc)	Female	3	2.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	6	10.6	56.8	(20.7-123.6)
Female	70	74.9	93.5	(72.9-118.1)	Female	8	9.2	86.7	(37.3-170.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	9	8.7	104.0	(47.5-197.5)
<u>Colon / Rectum</u>					Female	8	3.9	206.6	(89.0-407.1)
Male	33	20.4	161.7	(111.3-227.1)	<u>Ovary</u>				
Female	29	21.1	137.3	(92.0-197.3)	Female	2	6.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	5.0	100.6	(32.4-234.8)	Male	4	6.3	nc	(nc-nc)
Female	1	1.3	nc	(nc-nc)	Female	7	6.7	104.1	(41.7-214.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	67	66.8	100.2	(77.7-127.3)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	4	4.3	nc	(nc-nc)
Male	8	10.0	79.9	(34.4-157.4)	Female	2	2.7	nc	(nc-nc)
Female	8	5.9	135.0	(58.1-266.0)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.4	nc	(nc-nc)
Male	4	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	4.6	nc	(nc-nc)
<u>Leukemia</u>					Female	10	14.1	71.1	(34.1-130.8)
Male	7	7.2	96.7	(38.7-199.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	5.4	91.8	(29.6-214.2)	Female	14	17.3	81.0	(44.2-135.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	6.4	nc	(nc-nc)	Male	224	246.3	91.0	(79.4-103.7)
Female	2	2.1	nc	(nc-nc)	Female	235	254.5	92.4	(80.9-104.9)
<u>Lung and Bronchus</u>									
Male	31	32.9	94.2	(64.0-133.7)					
Female	32	35.2	90.9	(62.2-128.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Easton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	22.5	97.7	(61.2-147.9)	Male	19	15.1	125.6	(75.6-196.2)
Female	9	7.6	118.0	(53.9-224.1)	Female	17	11.9	142.3	(82.8-227.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	7	4.5	155.5	(62.3-320.4)	Male	4	4.4	nc	(nc-nc)
Female	6	3.8	159.3	(58.2-346.7)	Female	3	3.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.7	nc	(nc-nc)	Male	10	13.3	74.9	(35.9-137.8)
Female	117	92.1	127.1	(105.1-152.3)	Female	14	10.7	130.3	(71.2-218.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	3.3	nc	(nc-nc)	Male	9	11.1	80.8	(36.9-153.4)
<u>Colon / Rectum</u>					Female	3	4.6	nc	(nc-nc)
Male	21	25.4	82.6	(51.1-126.2)	<u>Ovary</u>				
Female	34	23.6	144.2	(99.9-201.5)	Female	8	8.3	95.9	(41.3-189.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	6.3	110.5	(44.3-227.7)	Male	6	7.9	76.4	(27.9-166.3)
Female	3	1.5	nc	(nc-nc)	Female	7	7.4	94.9	(38.0-195.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.0	nc	(nc-nc)	Male	74	87.0	85.1	(66.8-106.8)
Female	2	1.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	5	5.4	92.9	(29.9-216.7)
Male	15	13.0	115.3	(64.5-190.2)	Female	2	2.9	nc	(nc-nc)
Female	8	7.1	113.0	(48.7-222.7)	<u>Testis</u>				
<u>Larynx</u>					Male	5	3.1	159.7	(51.5-372.7)
Male	3	3.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	1.1	nc	(nc-nc)	Male	10	6.1	164.5	(78.7-302.5)
<u>Leukemia</u>					Female	24	18.2	132.1	(84.6-196.5)
Male	14	9.2	152.5	(83.3-256.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	6.4	109.2	(43.8-225.0)	Female	18	21.1	85.1	(50.4-134.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	8.1	86.1	(34.5-177.5)	Male	303	313.8	96.6	(86.0-108.1)
Female	2	2.4	nc	(nc-nc)	Female	354	302.9	116.9	(105.0-129.7)
<u>Lung and Bronchus</u>									
Male	37	41.8	88.5	(62.3-122.0)					
Female	39	40.9	95.4	(67.8-130.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Edgartown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	5.4	130.5	(52.3-268.9)	Male	11	3.5	315.1	(157.1-563.8)
Female	2	1.6	nc	(nc-nc)	Female	4	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	3.0	nc	(nc-nc)
Female	18	18.5	97.6	(57.8-154.2)	Female	3	2.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	2	2.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	0.9	nc	(nc-nc)
Male	5	5.9	84.9	(27.4-198.2)	<u>Ovary</u>				
Female	4	4.8	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.5	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	29	20.4	142.4	(95.3-204.5)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	2	1.3	nc	(nc-nc)
Male	2	3.0	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	5	3.3	149.8	(48.3-349.7)
Male	1	2.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.3	nc	(nc-nc)	Female	5	4.4	113.8	(36.7-265.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.9	nc	(nc-nc)	Male	80	72.8	109.9	(87.1-136.7)
Female	0	0.5	nc	(nc-nc)	Female	66	61.2	107.9	(83.4-137.2)
<u>Lung and Bronchus</u>									
Male	8	9.9	80.8	(34.8-159.2)					
Female	11	8.7	126.5	(63.1-226.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Egremont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.3	nc	(nc-nc)	Male	4	1.4	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	3	7.7	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.4	nc	(nc-nc)
Male	5	2.4	210.4	(67.8-491.0)	<u>Ovary</u>				
Female	3	2.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.8	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	6	8.3	72.0	(26.3-156.7)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.2	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.5	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.7	nc	(nc-nc)	Male	27	29.6	91.2	(60.1-132.6)
Female	0	0.2	nc	(nc-nc)	Female	16	26.5	60.3	(34.5-98.0)
<u>Lung and Bronchus</u>									
Male	4	4.3	nc	(nc-nc)					
Female	4	4.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Erving

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	2.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	4	7.9	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	6	2.3	262.1	(95.7-570.5)	<u>Ovary</u>				
Female	1	2.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	7.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	2	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.3	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.5	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.6	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	17	27.9	60.9	(35.5-97.5)
Female	0	0.2	nc	(nc-nc)	Female	19	26.6	71.5	(43.0-111.7)
<u>Lung and Bronchus</u>									
Male	3	3.7	nc	(nc-nc)					
Female	2	3.7	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Essex

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	4.4	136.0	(49.7-296.0)	Male	5	2.9	174.7	(56.3-407.6)
Female	0	1.3	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	8	15.3	52.2	(22.5-102.8)	Female	0	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	0.5	nc	(nc-nc)	Male	4	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.8	nc	(nc-nc)
Male	2	4.9	nc	(nc-nc)	<u>Ovary</u>				
Female	2	4.1	nc	(nc-nc)	Female	4	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.2	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	1	1.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	16.2	43.2	(17.3-89.0)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	1	1.0	nc	(nc-nc)
Male	2	2.4	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	2	2.9	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	3	3.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.6	nc	(nc-nc)	Male	55	59.3	92.8	(69.9-120.8)
Female	0	0.4	nc	(nc-nc)	Female	44	50.8	86.6	(62.9-116.3)
<u>Lung and Bronchus</u>									
Male	10	8.0	124.8	(59.8-229.6)					
Female	8	7.0	114.8	(49.4-226.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Everett

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	35.2	96.6	(66.9-135.0)	Male	18	24.0	75.0	(44.4-118.5)
Female	9	13.7	65.6	(29.9-124.6)	Female	6	21.1	28.4	(10.4-61.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	7.5	66.6	(21.5-155.3)	Male	8	6.8	118.2	(50.9-233.0)
Female	3	6.5	nc	(nc-nc)	Female	5	5.8	85.8	(27.6-200.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.1	nc	(nc-nc)	Male	15	21.3	70.4	(39.4-116.1)
Female	135	152.5	88.5	(74.2-104.8)	Female	15	18.7	80.1	(44.8-132.1)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	15	5.9	255.8	(143.0-421.9)	Male	19	16.6	114.4	(68.9-178.7)
<u>Colon / Rectum</u>					Female	6	7.7	77.5	(28.3-168.6)
Male	42	39.7	105.7	(76.2-142.9)	<u>Ovary</u>				
Female	40	42.5	94.2	(67.3-128.3)	Female	12	13.9	86.1	(44.4-150.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	9.3	85.8	(36.9-169.0)	Male	15	12.0	125.5	(70.2-207.0)
Female	2	2.6	nc	(nc-nc)	Female	17	13.4	127.2	(74.1-203.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	3.7	nc	(nc-nc)	Male	101	122.1	82.7	(67.4-100.5)
Female	5	3.1	162.5	(52.4-379.3)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	16	8.3	191.8	(109.6-311.5)
Male	24	19.8	120.9	(77.5-179.9)	Female	9	5.4	168.2	(76.8-319.3)
Female	15	12.1	123.8	(69.2-204.1)	<u>Testis</u>				
<u>Larynx</u>					Male	5	7.0	71.0	(22.9-165.7)
Male	4	5.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.8	nc	(nc-nc)	Male	8	10.1	79.2	(34.1-156.0)
<u>Leukemia</u>					Female	27	32.1	84.1	(55.4-122.3)
Male	7	15.0	46.8	(18.7-96.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	14	11.6	120.2	(65.7-201.7)	Female	28	33.6	83.2	(55.3-120.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	17	12.0	141.5	(82.4-226.6)	Male	465	477.4	97.4	(88.7-106.7)
Female	8	4.1	193.4	(83.3-381.2)	Female	515	520.6	98.9	(90.6-107.8)
<u>Lung and Bronchus</u>									
Male	86	63.2	136.1	(108.8-168.0)					
Female	104	70.9	146.8	(119.9-177.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fairhaven

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	26	22.0	118.1	(77.2-173.1)	Male	7	13.5	52.0	(20.8-107.2)
Female	15	8.7	171.4	(95.9-282.8)	Female	13	10.8	120.7	(64.2-206.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	3.6	nc	(nc-nc)	Male	6	4.0	149.0	(54.4-324.2)
Female	5	3.3	152.5	(49.1-355.9)	Female	2	3.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.7	nc	(nc-nc)	Male	9	11.9	75.4	(34.4-143.1)
Female	79	82.1	96.2	(76.2-119.9)	Female	10	11.0	91.2	(43.7-167.7)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	2.6	nc	(nc-nc)	Male	8	9.1	87.7	(37.8-172.9)
<u>Colon / Rectum</u>					Female	4	4.4	nc	(nc-nc)
Male	17	23.5	72.4	(42.2-116.0)	<u>Ovary</u>				
Female	26	26.4	98.4	(64.3-144.2)	Female	9	7.7	117.2	(53.5-222.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	5.6	nc	(nc-nc)	Male	6	7.3	82.3	(30.1-179.2)
Female	1	1.6	nc	(nc-nc)	Female	11	8.7	127.0	(63.3-227.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.4	nc	(nc-nc)	Male	92	72.7	126.6	(102.0-155.2)
Female	1	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	8	5.0	160.2	(69.0-315.8)
Male	17	10.9	156.5	(91.1-250.6)	Female	4	3.4	nc	(nc-nc)
Female	10	6.8	146.8	(70.3-270.0)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.2	nc	(nc-nc)
Male	8	3.0	262.7	(113.1-517.7)	<u>Thyroid</u>				
Female	3	1.0	nc	(nc-nc)	Male	5	4.7	106.8	(34.4-249.2)
<u>Leukemia</u>					Female	17	13.5	126.3	(73.5-202.2)
Male	13	8.3	157.3	(83.7-269.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	6.5	122.5	(52.7-241.3)	Female	17	18.6	91.4	(53.2-146.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.9	nc	(nc-nc)	Male	321	276.9	115.9	(103.6-129.3)
Female	1	2.5	nc	(nc-nc)	Female	319	292.3	109.1	(97.5-121.8)
<u>Lung and Bronchus</u>									
Male	60	38.7	155.0	(118.3-199.5)					
Female	54	42.7	126.4	(94.9-164.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fall River

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	105	92.1	114.1	(93.3-138.1)	Male	32	59.0	54.2	(37.1-76.5)
Female	34	38.4	88.6	(61.4-123.8)	Female	22	51.9	42.4	(26.6-64.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	19	17.3	110.1	(66.3-172.0)	Male	14	17.2	81.6	(44.6-136.9)
Female	11	16.1	68.3	(34.0-122.2)	Female	16	16.0	100.1	(57.2-162.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	2.9	nc	(nc-nc)	Male	47	52.4	89.7	(65.9-119.3)
Female	287	379.7	75.6	(67.1-84.9)	Female	60	49.7	120.7	(92.1-155.4)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	17	13.3	127.9	(74.4-204.7)	Male	43	40.5	106.2	(76.9-143.1)
<u>Colon / Rectum</u>					Female	16	20.2	79.1	(45.2-128.5)
Male	123	100.5	122.4	(101.8-146.1)	<u>Ovary</u>				
Female	131	116.9	112.0	(93.7-132.9)	Female	22	35.4	62.1	(38.9-94.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	21	23.9	87.9	(54.4-134.3)	Male	37	30.9	119.6	(84.2-164.9)
Female	5	7.3	68.8	(22.2-160.6)	Female	33	37.8	87.3	(60.1-122.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	11	7.7	143.5	(71.5-256.8)	Male	274	314.6	87.1	(77.1-98.0)
Female	6	6.9	87.1	(31.8-189.7)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	39	21.3	183.2	(130.2-250.4)
Male	44	48.3	91.1	(66.2-122.3)	Female	30	14.9	201.3	(135.8-287.5)
Female	35	31.2	112.1	(78.1-155.9)	<u>Testis</u>				
<u>Larynx</u>					Male	17	13.4	126.5	(73.6-202.5)
Male	21	13.1	159.8	(98.9-244.3)	<u>Thyroid</u>				
Female	11	4.7	235.3	(117.3-421.0)	Male	19	22.5	84.3	(50.8-131.7)
<u>Leukemia</u>					Female	82	71.0	115.6	(91.9-143.4)
Male	35	36.8	95.1	(66.2-132.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	43	30.5	140.9	(102.0-189.9)	Female	99	85.3	116.1	(94.4-141.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	29	29.9	96.9	(64.9-139.1)	Male	1287	1202.6	107.0	(101.3-113.0)
Female	14	11.1	126.2	(68.9-211.8)	Female	1321	1341.5	98.5	(93.2-103.9)
<u>Lung and Bronchus</u>									
Male	250	163.9	152.6	(134.2-172.7)					
Female	212	190.7	111.2	(96.7-127.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Falmouth

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	58	56.8	102.1	(77.5-132.0)	Male	28	33.0	84.8	(56.4-122.6)
Female	17	20.6	82.3	(47.9-131.8)	Female	33	24.3	135.8	(93.4-190.7)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	15	8.2	181.9	(101.7-300.0)	Male	9	10.1	89.0	(40.6-169.0)
Female	9	7.5	120.4	(54.9-228.5)	Female	9	8.6	104.8	(47.8-199.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.7	nc	(nc-nc)	Male	30	28.9	103.7	(69.9-148.0)
Female	215	193.0	111.4	(97.0-127.3)	Female	27	25.8	104.6	(68.9-152.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	5	5.6	88.7	(28.6-207.0)	Male	30	21.6	139.2	(93.9-198.7)
<u>Colon / Rectum</u>					Female	7	10.5	66.9	(26.8-137.9)
Male	59	57.7	102.2	(77.8-131.9)	<u>Ovary</u>				
Female	52	60.1	86.5	(64.6-113.5)	Female	22	18.0	122.4	(76.7-185.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	14.1	92.1	(49.0-157.4)	Male	13	18.6	70.0	(37.3-119.8)
Female	6	4.0	151.5	(55.3-329.8)	Female	19	20.2	94.2	(56.7-147.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	2.8	nc	(nc-nc)	Male	213	184.5	115.5	(100.5-132.1)
Female	3	2.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	11	12.5	87.8	(43.8-157.1)
Male	27	26.2	103.0	(67.9-149.9)	Female	3	7.6	nc	(nc-nc)
Female	12	16.3	73.8	(38.1-128.9)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.6	nc	(nc-nc)
Male	9	7.7	117.3	(53.5-222.8)	<u>Thyroid</u>				
Female	4	2.6	nc	(nc-nc)	Male	12	10.1	118.6	(61.2-207.2)
<u>Leukemia</u>					Female	14	28.5	49.2	(26.9-82.5)
Male	18	20.1	89.4	(52.9-141.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	9	14.8	60.6	(27.7-115.1)	Female	36	45.3	79.4	(55.6-110.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	18	16.8	107.4	(63.6-169.7)	Male	701	690.6	101.5	(94.1-109.3)
Female	3	6.0	nc	(nc-nc)	Female	666	685.0	97.2	(90.0-104.9)
<u>Lung and Bronchus</u>									
Male	68	101.1	67.2	(52.2-85.3)					
Female	112	106.1	105.6	(86.9-127.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Fitchburg

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	36	36.8	97.9	(68.5-135.5)	Male	16	24.3	65.8	(37.6-106.9)
Female	15	14.4	104.1	(58.2-171.7)	Female	14	20.8	67.4	(36.8-113.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	7.4	80.7	(29.5-175.7)	Male	13	7.0	185.3	(98.6-316.9)
Female	7	6.5	106.9	(42.8-220.3)	Female	8	6.1	131.9	(56.8-260.0)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.2	nc	(nc-nc)	Male	19	21.7	87.5	(52.7-136.7)
Female	130	150.5	86.4	(72.2-102.6)	Female	19	19.2	99.2	(59.7-154.9)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	9	5.4	165.2	(75.4-313.7)	Male	27	17.0	158.9	(104.7-231.2)
<u>Colon / Rectum</u>					Female	10	7.9	127.1	(60.8-233.7)
Male	31	41.0	75.7	(51.4-107.4)	<u>Ovary</u>				
Female	44	44.5	98.9	(71.9-132.8)	Female	12	14.0	85.5	(44.1-149.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	11	9.7	112.9	(56.3-202.1)	Male	12	12.4	96.6	(49.8-168.7)
Female	2	2.7	nc	(nc-nc)	Female	9	14.2	63.4	(28.9-120.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.5	nc	(nc-nc)	Male	112	128.3	87.3	(71.9-105.0)
Female	0	3.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	13	8.6	150.7	(80.1-257.7)
Male	22	20.1	109.4	(68.5-165.6)	Female	6	5.6	106.4	(38.8-231.5)
Female	11	12.2	90.4	(45.1-161.8)	<u>Testis</u>				
<u>Larynx</u>					Male	6	6.2	96.4	(35.2-209.8)
Male	1	5.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.8	nc	(nc-nc)	Male	4	9.8	nc	(nc-nc)
<u>Leukemia</u>					Female	23	29.8	77.2	(48.9-115.8)
Male	15	15.3	98.2	(54.9-161.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	11	12.0	92.0	(45.9-164.7)	Female	38	33.6	113.0	(79.9-155.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	12.5	79.8	(38.2-146.8)	Male	485	492.8	98.4	(89.8-107.6)
Female	3	4.3	nc	(nc-nc)	Female	502	524.0	95.8	(87.6-104.6)
<u>Lung and Bronchus</u>									
Male	87	66.0	131.8	(105.6-162.6)					
Female	87	72.4	120.2	(96.3-148.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Florida

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	3.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.2	nc	(nc-nc)
Male	0	1.2	nc	(nc-nc)	<u>Ovary</u>				
Female	0	0.8	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	4.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.1	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.6	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	14.7	54.4	(23.4-107.3)
Female	0	0.1	nc	(nc-nc)	Female	10	10.2	98.0	(46.9-180.3)
<u>Lung and Bronchus</u>									
Male	1	2.0	nc	(nc-nc)					
Female	3	1.4	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Foxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	17.7	84.8	(47.4-139.8)	Male	22	11.8	186.1	(116.6-281.8)
Female	5	6.2	80.3	(25.9-187.4)	Female	14	9.3	150.7	(82.3-252.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	3.5	143.6	(46.3-335.1)	Male	3	3.5	nc	(nc-nc)
Female	5	2.9	173.7	(56.0-405.3)	Female	1	2.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	13	10.4	124.9	(66.4-213.6)
Female	81	72.5	111.8	(88.8-138.9)	Female	6	8.6	70.1	(25.6-152.5)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	7	8.6	81.5	(32.6-167.9)
<u>Colon / Rectum</u>					Female	2	3.6	nc	(nc-nc)
Male	19	20.1	94.7	(57.0-147.9)	<u>Ovary</u>				
Female	16	19.1	83.7	(47.8-135.9)	Female	10	6.5	153.7	(73.6-282.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.9	nc	(nc-nc)	Male	5	6.1	81.8	(26.4-190.8)
Female	0	1.2	nc	(nc-nc)	Female	5	6.0	83.3	(26.8-194.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.5	nc	(nc-nc)	Male	70	66.4	105.5	(82.2-133.3)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	6	4.2	142.4	(52.0-309.9)
Male	8	10.1	79.1	(34.1-156.0)	Female	1	2.4	nc	(nc-nc)
Female	8	5.6	141.7	(61.0-279.3)	<u>Testis</u>				
<u>Larynx</u>					Male	2	2.4	nc	(nc-nc)
Male	0	2.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	5	4.7	106.3	(34.3-248.1)
<u>Leukemia</u>					Female	20	13.7	145.5	(88.8-224.8)
Male	8	7.1	112.3	(48.4-221.4)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.1	137.9	(55.2-284.1)	Female	18	16.4	109.9	(65.1-173.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	6.3	nc	(nc-nc)	Male	251	243.2	103.2	(90.8-116.8)
Female	1	1.9	nc	(nc-nc)	Female	257	240.1	107.1	(94.4-121.0)
<u>Lung and Bronchus</u>									
Male	30	32.7	91.8	(61.9-131.0)					
Female	32	33.3	96.0	(65.7-135.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Framingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	50	68.4	73.1	(54.3-96.4)	Male	41	44.8	91.5	(65.6-124.1)
Female	29	26.5	109.3	(73.2-156.9)	Female	29	37.8	76.7	(51.4-110.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	14	13.3	105.5	(57.6-177.1)	Male	17	12.9	131.6	(76.6-210.7)
Female	4	11.7	nc	(nc-nc)	Female	14	11.1	125.6	(68.6-210.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.1	nc	(nc-nc)	Male	38	39.7	95.7	(67.7-131.3)
Female	282	276.5	102.0	(90.4-114.6)	Female	36	35.1	102.6	(71.8-142.0)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	15	10.1	148.7	(83.2-245.3)	Male	29	30.9	93.8	(62.8-134.7)
<u>Colon / Rectum</u>					Female	7	14.4	48.6	(19.5-100.1)
Male	71	75.5	94.0	(73.4-118.6)	<u>Ovary</u>				
Female	88	82.0	107.4	(86.1-132.3)	Female	26	25.6	101.8	(66.4-149.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	15	17.9	83.7	(46.8-138.1)	Male	29	23.1	125.7	(84.2-180.5)
Female	8	5.0	159.1	(68.5-313.6)	Female	26	26.2	99.4	(64.9-145.6)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	6.0	83.1	(26.8-193.9)	Male	221	235.1	94.0	(82.0-107.3)
Female	7	5.1	136.6	(54.7-281.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	19	16.0	119.0	(71.6-185.9)
Male	44	36.9	119.3	(86.7-160.1)	Female	15	10.4	143.9	(80.5-237.4)
Female	16	22.2	72.0	(41.1-116.9)	<u>Testis</u>				
<u>Larynx</u>					Male	8	10.9	73.2	(31.5-144.3)
Male	5	9.9	50.6	(16.3-118.0)	<u>Thyroid</u>				
Female	3	3.3	nc	(nc-nc)	Male	20	17.7	113.1	(69.0-174.6)
<u>Leukemia</u>					Female	52	54.1	96.1	(71.7-126.0)
Male	29	27.8	104.5	(69.9-150.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	22	21.6	101.7	(63.7-154.0)	Female	62	61.6	100.7	(77.2-129.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	24	22.7	105.8	(67.8-157.4)	Male	852	904.6	94.2	(88.0-100.7)
Female	10	7.8	128.5	(61.5-236.3)	Female	989	959.6	103.1	(96.7-109.7)
<u>Lung and Bronchus</u>									
Male	106	122.1	86.8	(71.1-105.0)					
Female	134	132.3	101.3	(84.9-120.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- **Shading** indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

Franklin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 2008-2012

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	28	24.9	112.5	(74.7-162.5)	Male	17	17.8	95.6	(55.6-153.0)
Female	9	9.0	99.7	(45.5-189.4)	Female	17	15.1	112.4	(65.4-180.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	5.8	nc	(nc-nc)	Male	9	5.1	178.0	(81.2-338.0)
Female	4	4.8	nc	(nc-nc)	Female	3	4.0	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	8	15.8	50.5	(21.7-99.5)
Female	120	116.9	102.6	(85.1-122.7)	Female	14	13.0	107.4	(58.7-180.2)
<u>Cervix Uteri</u>					<u>Oral Cavity & Pharynx</u>				
Female	4	4.5	nc	(nc-nc)	Male	13	13.4	97.0	(51.6-166.0)
<u>Colon / Rectum</u>					Female	1	5.6	nc	(nc-nc)
Male	32	30.0	106.7	(72.9-150.6)	<u>Ovary</u>				
Female	32	28.9	110.6	(75.6-156.1)	Female	8	10.3	77.6	(33.4-152.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	7.1	126.9	(57.9-241.0)	Male	13	8.8	148.0	(78.7-253.0)
Female	3	1.7	nc	(nc-nc)	Female	6	8.7	68.8	(25.1-149.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	2.6	nc	(nc-nc)	Male	106	95.2	111.4	(91.2-134.7)
Female	6	2.1	290.6	(106.1-632.4)	<u>Stomach</u>				
<u>Kidney & Renal Pelvis</u>					Male	7	6.2	113.5	(45.5-233.9)
Male	13	15.5	83.8	(44.6-143.4)	Female	3	3.6	nc	(nc-nc)
Female	12	8.8	137.0	(70.7-239.4)	<u>Testis</u>				
<u>Larynx</u>					Male	5	4.4	113.2	(36.5-264.1)
Male	9	4.0	225.8	(103.0-428.7)	<u>Thyroid</u>				
Female	0	1.3	nc	(nc-nc)	Male	12	7.8	153.1	(79.0-267.5)
<u>Leukemia</u>					Female	30	24.5	122.5	(82.6-174.9)
Male	11	11.0	100.2	(50.0-179.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	8.0	62.3	(20.1-145.3)	Female	29	25.6	113.2	(75.8-162.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	11	9.5	115.9	(57.8-207.4)	Male	369	358.4	103.0	(92.7-114.0)
Female	2	2.9	nc	(nc-nc)	Female	377	375.7	100.4	(90.5-111.0)
<u>Lung and Bronchus</u>									
Male	35	45.8	76.4	(53.2-106.2)					
Female	40	48.1	83.1	(59.3-113.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ((Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;